Influence of aluminium hydroxide intake on haemoglobin concentrations and blood transfusion requirements in haemodialysis patients.
To investigate the likely influence of aluminium hydroxide intake (Al(OH)3) on haemoglobin concentrations and blood transfusion requirements we studied 27 long-term haemodialysis patients for 24 months divided in two equal periods: (P I and P II). All patients received oral iron as a fasting single dose, intravenous iron being used only occasionally. During P I Al(OH)3 was given thrice daily, during P II Al(OH)3 was reduced significantly by stopping the breakfast dose, thereby separating the oral iron from the influence of the binder. After Al(OH)3 reduction haemoglobin increased, the requirement for blood transfusion decreased, and the need for intravenous iron also decreased. Serum phosphorous did not change. This suggests that Al(OH)3 might interfere with erythropoiesis and we consider it advisable to avoid the morning dose of Al(OH)3 which in many cases is not necessary.
D000536:Aluminum Hydroxide / Q000008:administration & dosage* / Q000009:adverse effects; D001803:Blood Transfusion; D004920:Erythropoiesis / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006435:Renal Dialysis
D006454:Hemoglobins; D000536:Aluminum Hydroxide